Published in Cancer Res on May 01, 2008
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany NY) (2009) 2.49
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol (2011) 2.19
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Lamin B1 loss is a senescence-associated biomarker. Mol Biol Cell (2012) 2.03
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle (2012) 2.00
MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol (2010) 1.90
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A (2010) 1.77
Alterations in microRNA expression in stress-induced cellular senescence. Mech Ageing Dev (2009) 1.74
Role of miR-34c microRNA in the late steps of spermatogenesis. RNA (2010) 1.60
p53: guardian of ploidy. Mol Oncol (2011) 1.25
The p53 circuit board. Biochim Biophys Acta (2012) 1.24
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene (2011) 1.20
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
MiR-34 modulates Caenorhabditis elegans lifespan via repressing the autophagy gene atg9. Age (Dordr) (2011) 1.17
The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol (2009) 1.14
MicroRNAs in C. elegans Aging: Molecular Insurance for Robustness? Curr Genomics (2009) 1.11
Reviewing the current classification of inhibitor of growth family proteins. Cancer Sci (2009) 1.09
p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res (2014) 1.09
Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate. Aging (Albany NY) (2009) 1.07
p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis (2012) 1.06
MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. Cell Death Dis (2015) 1.05
Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry (2009) 1.05
Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. Exp Neurol (2011) 1.04
MicroRNA-34c enhances murine male germ cell apoptosis through targeting ATF1. PLoS One (2012) 1.03
Rapid and efficient hydrophilicity tuning of p53/mdm2 antagonists. J Comb Chem (2010) 1.03
Identifying microRNAs involved in degeneration of the organ of corti during age-related hearing loss. PLoS One (2013) 1.02
Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension. Circulation (2013) 1.01
Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells. Oncol Lett (2013) 1.01
Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem (2010) 1.01
Regulation of senescence by microRNA biogenesis factors. Ageing Res Rev (2012) 0.99
Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des (2011) 0.99
Cellular senescence and cancer chemotherapy resistance. Drug Resist Updat (2012) 0.99
miR-34a induces cellular senescence via modulation of telomerase activity in human hepatocellular carcinoma by targeting FoxM1/c-Myc pathway. Oncotarget (2015) 0.98
Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel. PLoS One (2011) 0.93
Cellular senescence mediated by p16INK4A-coupled miRNA pathways. Nucleic Acids Res (2013) 0.90
miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction. Sci Rep (2014) 0.90
Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment. BMC Cancer (2010) 0.90
The multifunctional sorting protein PACS-2 regulates SIRT1-mediated deacetylation of p53 to modulate p21-dependent cell-cycle arrest. Cell Rep (2014) 0.89
ING2 is upregulated in colon cancer and increases invasion by enhanced MMP13 expression. Int J Cancer (2009) 0.88
Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3. J Biol Chem (2009) 0.87
E2F1-dependent oncogenic addiction of melanoma cells to MDM2. Oncogene (2011) 0.87
ING proteins as potential anticancer drug targets. Curr Drug Targets (2009) 0.87
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer (2011) 0.86
miR-34a expression, epigenetic regulation, and function in human placental diseases. Epigenetics (2013) 0.86
miRNA gene counts in chromosomes vary widely in a species and biogenesis of miRNA largely depends on transcription or post-transcriptional processing of coding genes. Front Genet (2014) 0.86
Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease. PLoS One (2012) 0.85
Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas. PLoS One (2010) 0.85
The ING tumor suppressors in cellular senescence and chromatin. Cell Biosci (2011) 0.85
miR-34 miRNAs Regulate Cellular Senescence in Type II Alveolar Epithelial Cells of Patients with Idiopathic Pulmonary Fibrosis. PLoS One (2016) 0.83
A novel ING2 isoform, ING2b, synergizes with ING2a to prevent cell cycle arrest and apoptosis. FEBS Lett (2008) 0.83
Elevated miR-34c-5p mediates dermal fibroblast senescence by ultraviolet irradiation. Int J Biol Sci (2013) 0.82
Necdin, a p53-target gene, is an inhibitor of p53-mediated growth arrest. PLoS One (2012) 0.81
Modeling of miRNA and drug action in the EGFR signaling pathway. PLoS One (2012) 0.81
Amelioration of radiation esophagitis by orally administered p53/Mdm2/Mdm4 inhibitor (BEB55) or GS-nitroxide. In Vivo (2011) 0.80
ING2 controls the progression of DNA replication forks to maintain genome stability. EMBO Rep (2009) 0.80
'Junk' DNA meets the p53 network. Mol Syst Biol (2008) 0.80
The predictive effect of overexpressed miR-34a on good survival of cancer patients: a systematic review and meta-analysis. Onco Targets Ther (2015) 0.78
Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer. Oncotarget (2016) 0.78
CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Sci Rep (2016) 0.78
microRNA profiling in three main stages during porcine spermatogenesis. J Assist Reprod Genet (2015) 0.77
The cytoskeleton adaptor protein ankyrin-1 is upregulated by p53 following DNA damage and alters cell migration. Cell Death Dis (2016) 0.77
miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence. Am J Respir Cell Mol Biol (2016) 0.76
Ionizing radiation-induced microRNA expression changes in cultured RGC-5 cells. Mol Med Rep (2015) 0.76
Understanding drugs in breast cancer through drug sensitivity screening. Springerplus (2015) 0.75
New hope for Nutlin-3a therapy for pulmonary arterial hypertension. Front Pharmacol (2013) 0.75
Awakening p53 in senescent cells using nutlin-3. Aging (Albany NY) (2009) 0.75
INGs are potential drug targets for cancer. J Cancer Res Clin Oncol (2016) 0.75
Identification of Four Oxidative Stress-Responsive MicroRNAs, miR-34a-5p, miR-1915-3p, miR-638, and miR-150-3p, in Hepatocellular Carcinoma. Oxid Med Cell Longev (2017) 0.75
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
The serial cultivation of human diploid cell strains. Exp Cell Res (1961) 25.11
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Mdm2 promotes the rapid degradation of p53. Nature (1997) 21.26
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Genomic maps and comparative analysis of histone modifications in human and mouse. Cell (2005) 18.96
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 17.40
Active genes are tri-methylated at K4 of histone H3. Nature (2002) 15.68
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
p53 in health and disease. Nat Rev Mol Cell Biol (2007) 11.33
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark. Mol Cell (2007) 9.73
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51
ING2 PHD domain links histone H3 lysine 4 methylation to active gene repression. Nature (2006) 9.30
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell (1998) 8.33
Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature (2006) 7.52
Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00
ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell (2006) 5.01
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
Microarray analysis of replicative senescence. Curr Biol (1999) 4.25
MDM2 inhibitors for cancer therapy. Trends Mol Med (2006) 3.88
Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev (1999) 3.41
Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem (2004) 2.46
Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ (2003) 2.30
Regulation of cellular senescence by p53. Eur J Biochem (2001) 2.13
Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem (2000) 2.08
Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res (2006) 2.04
DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc Natl Acad Sci U S A (2001) 2.00
Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res (2007) 1.97
Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene (2003) 1.79
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene (2006) 1.78
MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood (2006) 1.71
Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol (2004) 1.55
p53 Activation by small molecules: application in oncology. J Med Chem (2005) 1.55
Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J (1999) 1.47
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res (2005) 1.42
Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. Oncogene (1998) 1.40
Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res (2000) 1.32
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol (2005) 1.31
ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res (2003) 1.25
Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol Ther (2003) 1.20
Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res (2007) 1.18
p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1. Endocrinology (1998) 1.14
Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene (2005) 1.10
Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene (2004) 1.09
Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem (2001) 1.08
Roles of cyclin D1 and related genes in growth inhibition, senescence and apoptosis. Apoptosis (1999) 1.07
Overexpression of cyclin D1 blocks proliferation of normal diploid fibroblasts. Exp Cell Res (1995) 1.01
Enhanced expression of cyclin D1 in senescent human fibroblasts. Mech Ageing Dev (1995) 0.88
Chromatin modification and senescence: linkage by tumor suppressors? Rejuvenation Res (2006) 0.79
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell (2005) 6.79
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol (2004) 5.82
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol (2004) 4.87
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J (2004) 4.26
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology (2009) 3.92
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet (2004) 3.89
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell (2007) 3.68
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res (2008) 3.56
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J (2002) 3.29
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab (2005) 3.15
A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res (2013) 3.08
The landscape of recombination in African Americans. Nature (2011) 3.06
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 3.02
BRAF mutations in papillary carcinomas of the thyroid. Oncogene (2003) 2.94
Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res (2011) 2.81
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling. Protein Sci (2007) 2.44
Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology (2009) 2.43
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell (2006) 2.39
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.33
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol (2005) 2.31
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
TP53 and liver carcinogenesis. Hum Mutat (2003) 2.23
Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer (2006) 2.11
Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle (2003) 2.10
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol (2006) 2.10
Thymidine phosphorylase gene mutation is not a primary cause of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Intern Med (2006) 2.09
p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res (2004) 2.08
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med (2006) 1.98
Gait disturbance due to foot drop is refractory to treatment in nonsystemic vasculitic neuropathy. Eur Neurol (2014) 1.97
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res (2003) 1.97
The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell (2009) 1.96
A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection. Immunity (2003) 1.95
Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One (2009) 1.94
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov (2013) 1.85
Delayed kinetics of DNA double-strand break processing in normal and pathological aging. Aging Cell (2007) 1.84
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol (2009) 1.84
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell (2006) 1.82
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol (2004) 1.82
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer (2010) 1.79
Homozygous deletion scanning of the lung cancer genome at a 100-kb resolution. Genes Chromosomes Cancer (2007) 1.77
POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol (2005) 1.74
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol (2011) 1.71
BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J (2003) 1.71
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res (2005) 1.70
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet (2013) 1.69
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67